by 
Nausea medicines play a vital role in treating nausea and vomiting associated with motion sickness, pregnancy, chemotherapy, and post-surgery pain. They help block signals from the inner ear and other brain areas that trigger nausea and vomiting from symptoms like dizziness, balance problems, and stomach upset. Oral anti-nausea drugs including antihistamines and 5-HT3 receptor antagonists are commonly prescribed. Transdermal motion sickness patches containing antihistamines can also provide relief for over 24 hours. The global nausea medicine market witnesses high demand due to rising cases of nausea arising due to increasing vehicle, air, and sea travel. Working from home due to the pandemic has also led to an increase in motion sickness reported from using laptops and computers for long hours.
The global Nausea Medicine Market is estimated to be valued at US$ 2.8 Bn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2024-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the nausea medicine market is the rising availability of newer formulations. Pharmaceutical companies are focusing on developing alternative routes of administration such as sublingual tablets and films, buccal patches, and orally disintegrating tablets for offering faster relief. This is due to the fact that oral pills and capsules take longer to get absorbed and show effect. Transdermal patches and gels are also gaining traction as they allow continuous delivery of drugs. Furthermore, there is an increased focus on developing combination drug formulations containing two or more antiemetic agents for targeting different receptor pathways and mechanisms involved in nausea and vomiting. This helps enhance the therapeutic effectiveness. Newer pipeline drugs with novel mechanisms of action are also being evaluated for expanding treatment options.
Porter’s Analysis
Threat of new entrants: Pharmaceutical industry requires significant R&D investment and regulatory approvals which makes entry barriers high for new companies.
Bargaining power of buyers: Large buyers such as government agencies and private hospitals can negotiate lower prices from manufacturers due to their high purchase volumes.
Bargaining power of suppliers: Few suppliers dominate key active ingredients and raw material supply which gives them significant bargaining power over drug makers.
Threat of new substitutes: Alternative treatments developed may pose threat, however nausea is generally acute condition with limited substitutes.
Competitive rivalry: Presence of many global and local playersresults in intense competition on basis of drug efficacy, strong brand positioning and marketing.
Key Takeaways
The global Nausea Medicine Market is expected to witness high growth. The market size for 2024 is US$ 2.8 Bn registering a CAGR of 6.3% during the forecast period of 2023 to 2030.
Regional analysis
North America dominates the nausea medicine market currently due to high healthcare spending and major presence of global key players. However, Asia Pacific region is expected to show highest growth rate owing to rising cases of chemotherapy-related nausea in countries like India and China.
Key players
Key players operating in the Nausea Medicine Market are GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company.
Nausea medicines play a vital role in treating nausea and vomiting associated with motion sickness, pregnancy, chemotherapy, and post-surgery pain. They help block signals from the inner ear and other brain areas that trigger nausea and vomiting from symptoms like dizziness, balance problems, and stomach upset. Oral anti-nausea drugs including antihistamines and 5-HT3 receptor antagonists are commonly prescribed. Transdermal motion sickness patches containing antihistamines can also provide relief for over 24 hours. The global nausea medicine market witnesses high demand due to rising cases of nausea arising due to increasing vehicle, air, and sea travel. Working from home due to the pandemic has also led to an increase in motion sickness reported from using laptops and computers for long hours.
The global Nausea Medicine Market is estimated to be valued at US$ 2.8 Bn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2024-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the nausea medicine market is the rising availability of newer formulations. Pharmaceutical companies are focusing on developing alternative routes of administration such as sublingual tablets and films, buccal patches, and orally disintegrating tablets for offering faster relief. This is due to the fact that oral pills and capsules take longer to get absorbed and show effect. Transdermal patches and gels are also gaining traction as they allow continuous delivery of drugs. Furthermore, there is an increased focus on developing combination drug formulations containing two or more antiemetic agents for targeting different receptor pathways and mechanisms involved in nausea and vomiting. This helps enhance the therapeutic effectiveness. Newer pipeline drugs with novel mechanisms of action are also being evaluated for expanding treatment options.
Porter’s Analysis
Threat of new entrants: Pharmaceutical industry requires significant R&D investment and regulatory approvals which makes entry barriers high for new companies.
Bargaining power of buyers: Large buyers such as government agencies and private hospitals can negotiate lower prices from manufacturers due to their high purchase volumes.
Bargaining power of suppliers: Few suppliers dominate key active ingredients and raw material supply which gives them significant bargaining power over drug makers.
Threat of new substitutes: Alternative treatments developed may pose threat, however nausea is generally acute condition with limited substitutes.
Competitive rivalry: Presence of many global and local playersresults in intense competition on basis of drug efficacy, strong brand positioning and marketing.
Key Takeaways
The global Nausea Medicine Market is expected to witness high growth. The market size for 2024 is US$ 2.8 Bn registering a CAGR of 6.3% during the forecast period of 2023 to 2030.
Regional analysis
North America dominates the nausea medicine market currently due to high healthcare spending and major presence of global key players. However, Asia Pacific region is expected to show highest growth rate owing to rising cases of chemotherapy-related nausea in countries like India and China.
Key players
Key players operating in the Nausea Medicine Market are GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
